White House appoints NCI Director Andrew von Eschenbach acting FDA commissioner after Lester Crawford resigns.
Von Eschenbach says he will continue as NCI director and give both jobs “100 percent.”
Members of Congress say that won’t work.
Legal experts say too many conflicts involved. HHS gave von Eschenbach a waiver for his role in C-Change.
After a “humble” start at NCI, von Eschenbach set unachievable goal.
Trending Stories
- NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- Did Vinay Prasad need to mention the Nazis to make a point on the U.S. pandemic response?
- Cyber-iconoclast Vinay Prasad named head of FDA’s CBER
An oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies - Prasad: FDA has confused merely approving drugs with making the world a better place